Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Upregulated Tie2 expression in plasma: a potential non-invasive biomarker for the diagnosis of breast cancer

Upregulated Tie2 expression in plasma: a potential non-invasive biomarker for the diagnosis of... Breast cancer is by far the most common malignancy found in women and causes a significant public health problem around the world. Early diagnosis of cancer plays an important role in successful treatment and survival of patients. This study aims to investigate the possibility of plasma Tie2 to be used as a biomarker for diagnosis of breast cancer. In total, 20 healthy volunteers and 33 breast cancer patients were considered for this study. The level of Tie2 in plasma was detected using the ELISA technique and immunohistochemistry was performed to measure the expression of Tie2 in normal and breast cancer tissues. Plasma concentrations of Tie2 were significantly higher among breast cancer patients compared to healthy subjects, and both mRNA and protein expression of Tie2 were higher in breast cancer tissue than in normal tissue. Plasma concentrations of Tie2 were positively correlated with the grade of breast cancer. Finally, in vitro knockdown of Tie2 expression in a breast adenocarcinoma cell line inhibited the proliferation of these cells. It is concluded from the results that Tie2 might be a useful plasma biomarker for the early detection of breast cancer and could be developed to be a target for novel drug discovery. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Cytokine Network Springer Journals

Upregulated Tie2 expression in plasma: a potential non-invasive biomarker for the diagnosis of breast cancer

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/upregulated-tie2-expression-in-plasma-a-potential-non-invasive-vFF0EnQUhc
Publisher
Springer Journals
Copyright
Copyright © JLE/Springer 2021
eISSN
1952-4005
DOI
10.1684/ecn.2021.0468
Publisher site
See Article on Publisher Site

Abstract

Breast cancer is by far the most common malignancy found in women and causes a significant public health problem around the world. Early diagnosis of cancer plays an important role in successful treatment and survival of patients. This study aims to investigate the possibility of plasma Tie2 to be used as a biomarker for diagnosis of breast cancer. In total, 20 healthy volunteers and 33 breast cancer patients were considered for this study. The level of Tie2 in plasma was detected using the ELISA technique and immunohistochemistry was performed to measure the expression of Tie2 in normal and breast cancer tissues. Plasma concentrations of Tie2 were significantly higher among breast cancer patients compared to healthy subjects, and both mRNA and protein expression of Tie2 were higher in breast cancer tissue than in normal tissue. Plasma concentrations of Tie2 were positively correlated with the grade of breast cancer. Finally, in vitro knockdown of Tie2 expression in a breast adenocarcinoma cell line inhibited the proliferation of these cells. It is concluded from the results that Tie2 might be a useful plasma biomarker for the early detection of breast cancer and could be developed to be a target for novel drug discovery.

Journal

European Cytokine Network – Springer Journals

Published: Aug 11, 2021

Keywords: Tie2; biomarker; breast cancer; non-invasive diagnosis; plasma

References

  • Risk determination and prevention of breast cancer
    Howell, A; Anderson, AS; Clarke, RB
  • Ultrasound imaging technologies for breast cancer detection and management: a review
    Guo, R; Lu, G; Qin, B; Fei, B
  • Distinct effects of body mass index and waist/hip ratio on risk of breast cancer by joint estrogen and progestogen receptor status: results from a case-control study in northern and Eastern China and implications for chemoprevention
    Wang, F; Liu, L; Cui, S
  • State of the evidence 2017: an update on the connection between breast cancer and the environment
    Gray, JM; Rasanayagam, S; Engel, C; Rizzo, J
  • Patient-derived xenograft (PDX) models in basic and translational breast cancer research
    Dobrolecki, LE; Airhart, SD; Alferez, DG
  • Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention
    Tharmapalan, P; Mahendralingam, M; Berman, HK; Khokha, R
  • High-throughput analysis of plasma hybrid markers for early detection of cancers
    Rho, JH; Lampe, PD
  • Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization
    Leppänen, VM; Saharinen, P; Alitalo, K
  • Dimerization of Tie2 mediated by its membrane-proximal FNIII domains
    Moore, JO; Lemmon, MA; Ferguson, KM
  • Role of angiopoietin/tie 2 in critical illness: promising biomarker, disease mediator, and therapeutic target?
    Lukasz, A; Kümpers, P; David, S
  • Tie2 regulates tumor metastasis of oral squamous cell carcinomas
    Kitajima, D; Kasamatsu, A; Nakashima, D
  • Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
    Jayson, GC; Zhou, C; Backen, A
  • The role of serum angiopoietin-2 levels in progression and prognosis of lung cancer: a meta-analysis
    Xu, Y; Zhang, Y; Wang, Z; Chen, N; Zhou, J; Liu, L
  • Recent advances in gastric cancer early diagnosis
    Necula, L; Matei, L; Dragu, D
  • Noninvasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy
    Springer, SU; Chen, CH; Rodriguez Pena, MDC
  • Macrophages orchestrate breast cancer early dissemination and metastasis
    Linde, N; Casanova-Acebes, M; Sosa, MS
  • The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2 (hi) macrophages in breast cancer and pancreatic neuroendocrine tumors
    Harney, AS; Karagiannis, GS; Pignatelli, J
  • Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer
    Forget, MA; Voorhees, JL; Cole, SL
  • Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
    Grenga, I; Kwilas, AR; Donahue, RN; Farsaci, B; Hodge, JW
  • Soluble Tie2 overrides the heightened invasion induced by antiangiogenesis therapies in gliomas
    Cortes-Santiago, N; Hossain, MB; Gabrusiewicz, K
  • Paracrine effect of GTP cyclohydrolase and angiopoietin-1 interaction in stromal fibroblasts on tumor Tie2 activation and breast cancer growth
    Chen, L; Zeng, X; Kleibeuker, E
  • Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer
    Matsuda, N; Lim, B; Wang, X; Ueno, NT
  • Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure
    Chong, AY; Caine, GJ; Freestone, B; Blann, AD; Lip, GY
  • Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]
    Nadar, SK; Blann, A; Beevers, DG; Lip, GY